カテゴリー： 世界, 医療/バイオ, Grand View Research

世界の生物製剤市場2023-2030：由来別（微生物、哺乳類）、製品別（MAB、組換えタンパク質、アンチセンス・RNAi）、疾患カテゴリー別、製造別、地域別

【英語タイトル】Biologics Market Size, Share & Trends Analysis Report By Source (Microbial, Mammalian), By Product (MABs, Recombinant Proteins, Antisense & RNAi), By Disease Category, By Manufacturing, By Region, And Segment Forecasts, 2023 - 2030

Grand View Researchが出版した調査資料（GRV23JUN020）・商品コード：GRV23JUN020
・発行会社（調査会社）：Grand View Research
・発行日：2023年5月29日
・ページ数：120
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後3営業日）
・調査対象地域：グローバル
・産業分野：バイオ
◆販売価格オプション（消費税別）
Single UserUSD5,950 ⇒換算￥904,400見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算￥1,056,400見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算￥1,360,400見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

Grand View Research社の市場調査書によると、世界の生物製剤市場規模が、予測期間中（2023年～2030年）に年平均10.3％増加し、2030年までに10,093.7億ドルへ達すると見込まれています。本調査書では、生物製剤の世界市場を調査対象とし、調査手法・範囲、エグゼクティブサマリー、市場変動・動向・範囲、由来別（微生物、哺乳類、その他）分析、製品別（モノクローナル抗体、ワクチン、組換えタンパク質、アンチセンス・RNAi治療薬、その他）分析、製造別（アウトソーシング、インハウス）分析、疾患別（腫瘍、感染症、免疫疾患、心血管疾患、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などについて調査・分析し、まとめています。なお、こちらに掲載されている企業情報には、Samsung BioLogics、Amgen、Novo Nordisk A/S、AbbVie Inc.、Sanofi、Johnson & Johnson Services, Inc、Celltrion、Bristol-Myers Squibb Company、Eli Lilly and Companyなどが含まれています。
・調査手法・範囲
・エグゼクティブサマリー
・市場変動・動向・範囲
・世界生物製剤の市場規模：由来別
- 微生物由来生物製剤の市場規模
- 哺乳類由来生物製剤の市場規模
- その他由来生物製剤の市場規模
・世界生物製剤の市場規模：製品別
- モノクローナル抗体の市場規模
- ワクチンの市場規模
- 組換えタンパク質の市場規模
- アンチセンス・RNAi治療薬の市場規模
- その他生物製剤の市場規模
・世界生物製剤の市場規模：製造別
- アウトソーシングにおける市場規模
- インハウスにおける市場規模
・世界生物製剤の市場規模：疾患別
- 腫瘍における市場規
- 感染症における市場規
- 免疫疾患における市場規
- 心血管疾患における市場規
- その他疾患における市場規
・世界生物製剤の市場規模：地域別
- 北米の生物製剤市場規模
- ヨーロッパの生物製剤市場規模
- アジア太平洋の生物製剤市場規模
- 中南米の生物製剤市場規模
- 中東・アフリカの生物製剤市場規模
・競争状況

生物製剤市場の成長と動向

Grand View Research社の最新レポートによると、世界の生物製剤市場規模は2030年までに1兆0093億7000万米ドルに達する見込みです。同市場は、2023年から2030年にかけて年平均成長率10.3％で拡大すると予測されています。がん、神経疾患、遺伝性疾患、自己免疫疾患の負担の増加、遺伝子治療、RNAi治療薬、抗体薬物複合体などの新規生物学的製剤の承認が、生物製剤市場を牽引するいくつかの要因です。

2022年現在、米国で承認されている細胞・遺伝子治療薬はすでに27品目あり、そのうち5品目が同年承認されています。Sarepta社の遺伝子治療薬SRP-9001は、デュシェンヌ型筋ジストロフィーの治療薬として現在第3相試験中で、PDUFA期日は2023年5月29日に設定されています。パイプラインにあるその他の遺伝子治療候補としては、ジストロフィー性表皮水疱症に対するKrystal BiotechのBeremagene geperpavec（B-VEC）、ハンチントン病に対するUniQureのAMT-130、トランスサイレチン（ATTR）アミロイドーシスに対するIntelliaのNTLA-2001およびNTLA-2002、血友病Bに対するNanoscopeのMCO-010およびPfizerのFidanacogene elaparvovecがあります。これらの遺伝子治療候補薬の承認とその後の商業化は、生物製剤市場の成長を促進すると予想されます。

モノクローナル抗体は、承認された生物製剤の中で最も多い数を占めています。従来のモノクローナル抗体の承認が鈍化する一方で、二重特異性モノクローナル抗体、抗体フラグメント、放射性免疫療法、ナノボディ、抗体薬物複合体などの次世代抗体がこの分野の成長を牽引しています。例えば、2021年9月、米国FDAは子宮頸がん治療用の新しい抗体薬物複合体であるSeagen社のTivdakを承認しました。

生物製剤市場は、主にその開発と生産に関連する高コストに関連する大きな課題に直面しています。生物製剤は複雑な化合物であるため、特殊な製造手順が必要となり、開発コストが法外に高くつく可能性があります。さらに、バイオシミラーとの競争激化も市場の主要な抑制要因となっています。2021年に欧州で承認された新規バイオシミラー医薬品は7品目であり、2020年に承認された9品目からわずかに減少しています。予測期間中、生物学的製剤が特許切れに直面する主な治療分野は、がん、内分泌、血液関連疾患であると予想されます。

生物製剤市場レポートハイライト

– 由来別では、哺乳類発現システムセグメントが予測期間中に最も速いCAGRで成長すると予測されます。微生物発現系は2022年の市場で首位に立ちました。

– 疾患カテゴリーに基づくと、2022年の生物製剤市場はがん分野が28.40%のシェアを占めました。モノクローナル抗体やその他の生物学的製剤のほとんどが、がんを適応症として承認されています。

– 血液疾患分野は、血友病に対する遺伝子治療候補薬の承認により、予測期間中に最も速いCAGRで拡大すると予想されます。

– 製品別では、モノクローナル抗体分野が2022年に66.42%のシェアを占め、市場を席巻しました。

– 2022年の生物製剤市場において、北米が最大の収益を生み出す地域でした。高コストの生物製剤に対する有利な償還政策が利用可能であること、大手企業が存在すること、研究開発への投資が多いことなどが、この地域が優位を占める主な要因です。

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

Table of Contents

Chapter 1. Methodology and Scope
1.1 Market Segmentation and Scope
1.1.1 Segment Definitions
1.1.1.1 Disease
1.1.1.2 Product
1.1.1.3 Source
1.1.1.4 Manufacturing site
1.2 Regional Scope
1.3 Estimates and Forecast Timeline
1.4 Objectives
1.4.1 Objective – 1
1.4.2 Objective – 2
1.4.3 Objective – 3
1.5 Research Methodology
1.6 Information Procurement
1.6.1 Purchased Database
1.6.2 GVR’s Internal Database
1.6.3 Secondary Sources
1.6.4 Primary Research
1.7 Information or Data Analysis
1.7.1 Data Analysis Models
1.8 Market Formulation & Validation
1.9 Model Details
1.9.1 Commodity Flow Analysis
1.10 List of Secondary Sources
1.11 List of Abbreviations
Chapter 2. Executive Summary
2.1 Market Outlook
2.2 Segment Insights
Chapter 3. Biologics Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.2. Penetration and Growth Prospect Mapping
3.3. User Perspective Analysis
3.4. Market Dynamics
3.4.1. Market Dynamics
3.4.1.1. Advancements in biomedical science
3.4.1.2. Rise in biologics contract manufacturing services
3.4.1.3. Several drugs going off patents
3.4.1.4. Commercial success of biologics
3.4.2. Market Restraint Analysis
3.4.2.1. Pharmacokinetics challenges associated with biologics
3.4.2.2. Rising control & cost for accessing biologics
3.4.2.3. Development of biosimilars
3.5. Biologics -Swot Analysis, By Factor (Political & Legal, Economic And Technological)
3.6. Industry Analysis – Porter’s
3.7. Biologics: Pipeline Analysis
Chapter 4. Biologics Market: Segment Analysis, By Source, 2018 – 2030 (USD Billion)
4.1. Global Biologics Market: Source Movement Analysis
4.2. Microbial Source
4.2.1. Global microbial source market, 2018 – 2030 (USD Billion)
4.3. Mammalian Source
4.3.1. Global mammalian source market, 2018 – 2030 (USD Billion)
4.4. Others
4.4.1. Global other source market, 2018 – 2030 (USD Billion)
Chapter 5. Biologics Market: Segment Analysis, By Product, 2018 – 2030 (USD Billion)
5.1. Global Biologics Market: Product Movement Analysis
5.2. Monoclonal Antibodies
5.2.1. Global monoclonal antibodies market, 2018 – 2030 (USD Billion)
5.2.2. Monoclonal antibodies by application
5.2.2.1. Diagnostic monoclonal antibodies
5.2.2.1.1. Diagnostic MABs market, 2018 – 2030 (USD Billion)
5.2.2.1.2. Diagnostic MABs for biochemical analysis
5.2.2.1.3. Diagnostic MABs for imaging
5.2.2.2. Therapeutic MABs
5.2.2.2.1. Therapeutic MABs market, 2018 – 2030 (USD Billion)
5.2.2.2.2. Direct MABs
5.2.2.2.3. Targeting MABs
5.2.2.3. Protein purification MABs
5.2.2.3.1. Protein purification MABs market, 2018 – 2030 (USD Billion)
5.2.2.4. Other MABs
5.2.2.4.1. Other MABs market, 2018 – 2030 (USD Billion)
5.2.3. Monoclonal antibodies by type
5.2.3.1. Murine MABs
5.2.3.1.1. Murine MABs market, 2018 – 2030 (USD Billion)
5.2.3.2. Chimeric MABs
5.2.3.2.1. Chimeric MABs market, 2018 – 2030 (USD Billion)
5.2.3.3. Humanized MABs
5.2.3.3.1. Humanized MABs market, 2018 – 2030 (USD Billion)
5.2.3.4. Human MABs
5.2.3.4.1. Human MABs market, 2018 – 2030 (USD Billion)
5.2.3.5. Other MABs
5.2.3.5.1. Other MABs market, 2018 – 2030 (USD Billion)
5.3. Vaccines
5.3.1. Global vaccines market, 2018 – 2030 (USD Billion)
5.4. Recombinant Proteins
5.4.1. Global recombinant proteins market, 2018 – 2030 (USD Billion)
5.5. Antisense & RNAi Therapeutics
5.5.1. Global Antisense & RNAi Therapeutics market, 2018 – 2030 (USD Billion)
5.6. Others
5.6.1. Global other product market, 2018 – 2030 (USD Billion)
Chapter 6. Biologics Market: Segment Analysis, By Manufacturing, 2018 – 2030 (USD Billion)
6.1. Global Biologics Market: Manufacturing Movement Analysis
6.2. Outsourced
6.2.1. Global outsourced market, 2018 – 2030 (USD Billion)
6.3. In-house
6.3.1. Global in-house market, 2018 – 2030 (USD Billion)
Chapter 7. Biologics Market: Segment Analysis, By Disease, 2018 – 2030 (USD Billion)
7.1. Global Biologics Market: Disease Category Movement Analysis
7.2. Oncology
7.2.1. Global oncology market, 2018 – 2030 (USD Billion)
7.2.2. MABs market for oncology
7.2.2.1. Global MABs market for oncology, 2018 – 2030 (USD Billion)
7.2.3. Vaccines market for oncology
7.2.3.1. Global vaccines market for oncology, 2018 – 2030 (USD Billion)
7.2.4. Recombinant proteins market for oncology
7.2.4.1. Global recombinant proteins market for oncology, 2018 – 2030 (USD Billion)
7.2.5. Antisense & RNAi Therapeutics market for oncology
7.2.5.1. Global Antisense & RNAi Therapeutics market for oncology, 2018 – 2030 (USD Billion)
7.2.6. Other products market for oncology
7.2.6.1. Global products market for oncology, 2018 – 2030 (USD Billion)
7.3. Infectious Disease
7.3.1. Global infectious disease market, 2018 – 2030 (USD Billion)
7.3.2. Vaccines market for infectious disease
7.3.2.1. Global vaccines market for infectious disease, 2018 – 2030 (USD Billion)
7.3.3. MABs market for infectious disease
7.3.3.1. Global MABs market for infectious disease, 2018 – 2030 (USD Billion)
7.3.4. Antisense & RNAi Therapeutics market for infectious disease
7.3.4.1. Global Antisense & RNAi Therapeutics market for infectious disease, 2018 – 2030 (USD Billion)
7.3.5. Recombinant proteins market for infectious disease
7.3.5.1. Global recombinant proteins market for infectious disease, 2018 – 2030 (USD Billion)
7.3.6. Other products market for infectious disease
7.3.6.1. Global products market for infectious disease, 2018 – 2030 (USD Billion)
7.4. Immunological Disorders
7.4.1. Global immunological disorders market, 2018 – 2030 (USD Billion)
7.5. Cardiovascular disorders
7.5.1. Global cardiovascular disorders market, 2018 – 2030 (USD Billion)
7.6. Hematologic Disorders
7.6.1. Global hematologic disorders market, 2018 – 2030 (USD Billion)
7.7. Others
7.7.1. Global other indications market, 2018 – 2030 (USD Billion)
Chapter 8. Biologics Market: Segment Analysis, By Region, 2018 – 2030 (USD Billion)
8.1 Biologics Market: Regional Outlook
8.2 North America
8.2.1 North America Biologics Market Estimates & Forecasts, 2018 – 2030 (USD Billion)
8.2.2 U.S.
8.2.2.1 Key Country Dynamics
8.2.2.2 U.S. Biologics Market Estimates & Forecasts, 2018 – 2030 (USD Billion)
8.2.2.3 Target Disease Prevalence
8.2.2.4 Competitive Scenario
8.2.2.5 Regulatory Framework
8.2.2.6 Reimbursement Scenario
8.2.3 Canada
8.2.3.1 Key Country Dynamics
8.2.3.2 Canada Biologics Market Estimates & Forecasts, 2018 – 2030 (USD Billion)
8.2.3.3 Target Disease Prevalence
8.2.3.4 Competitive Scenario
8.2.3.5 Regulatory Framework
8.2.3.6 Reimbursement Scenario
8.3 Europe
8.3.1 Europe Biologics Market Estimates & Forecasts, 2018 – 2030 (USD Billion)
8.3.2 UK
8.3.2.1 Key Country Dynamics
8.3.2.2 UK Biologics Market Estimates & Forecasts, 2018 – 2030 (USD Billion)
8.3.2.3 Target Disease Prevalence
8.3.2.4 Competitive Scenario
8.3.2.5 Regulatory Framework
8.3.2.6 Reimbursement Scenario
8.3.3 Germany
8.3.3.1 Key Country Dynamics
8.3.3.2 Germany Biologics Market Estimates & Forecasts, 2018 – 2030 (USD Billion)
8.3.3.3 Target Disease Prevalence
8.3.3.4 Competitive Scenario
8.3.3.5 Regulatory Framework
8.3.3.6 Reimbursement Scenario
8.3.4 France
8.3.4.1 Key Country Dynamics
8.3.4.2 France Biologics Market Estimates & Forecasts, 2018 – 2030 (USD Billion)
8.3.4.3 Target Disease Prevalence
8.3.4.4 Competitive Scenario
8.3.4.5 Regulatory Framework
8.3.4.6 Reimbursement Scenario
8.3.5 Italy
8.3.5.1 Key Country Dynamics
8.3.5.2 Italy Biologics Market Estimates & Forecasts, 2018 – 2030 (USD Billion)
8.3.5.3 Target Disease Prevalence
8.3.5.4 Competitive Scenario
8.3.5.5 Regulatory Framework
8.3.5.6 Reimbursement Scenario
8.3.6 Spain
8.3.6.1 Key Country Dynamics
8.3.6.2 Spain Biologics Market Estimates & Forecasts, 2018 – 2030 (USD Billion)
8.3.6.3 Target Disease Prevalence
8.3.6.4 Competitive Scenario
8.3.6.5 Regulatory Framework
8.3.6.6 Reimbursement Scenario
8.3.7 Denmark
8.3.7.1 Key Country Dynamics
8.3.7.2 Denmark Biologics Market Estimates & Forecasts, 2018 – 2030 (USD Billion)
8.3.7.3 Target Disease Prevalence
8.3.7.4 Competitive Scenario
8.3.7.5 Regulatory Framework
8.3.7.6 Reimbursement Scenario
8.3.8 Sweden
8.3.8.1 Key Country Dynamics
8.3.8.2 Sweden Biologics Market Estimates & Forecasts, 2018 – 2030 (USD Billion)
8.3.8.3 Target Disease Prevalence
8.3.8.4 Competitive Scenario
8.3.8.5 Regulatory Framework
8.3.8.6 Reimbursement Scenario
8.3.9 Norway
8.3.9.1 Key Country Dynamics
8.3.9.2 Norway Biologics Market Estimates & Forecasts, 2018 – 2030 (USD Billion)
8.3.9.3 Target Disease Prevalence
8.3.9.4 Competitive Scenario
8.3.9.5 Regulatory Framework
8.3.9.6 Reimbursement Scenario
8.4 Asia Pacific
8.4.1 Asia Pacific Biologics Market Estimates & Forecasts, 2018 – 2030 (USD Billion)
8.4.2 Japan
8.4.2.1 Key Country Dynamics
8.4.2.2 Japan Biologics Market Estimates & Forecasts, 2018 – 2030 (USD Billion)
8.4.2.3 Target Disease Prevalence
8.4.2.4 Competitive Scenario
8.4.2.5 Regulatory Framework
8.4.2.6 Reimbursement Scenario
8.4.3 China
8.4.3.1 Key Country Dynamics
8.4.3.2 China Biologics Market Estimates & Forecasts, 2018 – 2030 (USD Billion)
8.4.3.3 Target Disease Prevalence
8.4.3.4 Competitive Scenario
8.4.3.5 Regulatory Framework
8.4.3.6 Reimbursement Scenario
8.4.4 India
8.4.4.1 Key Country Dynamics
8.4.4.2 India Biologics Market Estimates & Forecasts, 2018 – 2030 (USD Billion)
8.4.4.3 Target Disease Prevalence
8.4.4.4 Competitive Scenario
8.4.4.5 Regulatory Framework
8.4.4.6 Reimbursement Scenario
8.4.5 Australia
8.4.5.1 Key Country Dynamics
8.4.5.2 Australia Biologics Market Estimates & Forecasts, 2018 – 2030 (USD Billion)
8.4.5.3 Target Disease Prevalence
8.4.5.4 Competitive Scenario
8.4.5.5 Regulatory Framework
8.4.5.6 Reimbursement Scenario
8.4.6 South Korea
8.4.6.1 Key Country Dynamics
8.4.6.2 South Korea Biologics Market Estimates & Forecasts, 2018 – 2030 (USD Billion)
8.4.6.3 Target Disease Prevalence
8.4.6.4 Competitive Scenario
8.4.6.5 Regulatory Framework
8.4.6.6 Reimbursement Scenario
8.4.7 Thailand
8.4.7.1 Key Country Dynamics
8.4.7.2 Thailand Biologics Market Estimates & Forecasts, 2018 – 2030 (USD Billion)
8.4.7.3 Target Disease Prevalence
8.4.7.4 Competitive Scenario
8.4.7.5 Regulatory Framework
8.4.7.6 Reimbursement Scenario
8.5 Latin America
8.5.1 Latin America Biologics Market Estimates & Forecasts, 2018 – 2030 (USD Billion)
8.5.2 Brazil
8.5.2.1 Key Country Dynamics
8.5.2.2 Brazil Biologics Market Estimates & Forecasts, 2018 – 2030 (USD Billion)
8.5.2.3 Target Disease Prevalence
8.5.2.4 Competitive Scenario
8.5.2.5 Regulatory Framework
8.5.2.6 Reimbursement Scenario
8.5.3 Mexico
8.5.3.1 Key Country Dynamics
8.5.3.2 Mexico Biologics Market Estimates & Forecasts, 2018 – 2030 (USD Billion)
8.5.3.3 Target Disease Prevalence
8.5.3.4 Competitive Scenario
8.5.3.5 Regulatory Framework
8.5.3.6 Reimbursement Scenario
8.5.4 Argentina
8.5.4.1 Key Country Dynamics
8.5.4.2 Argentina Biologics Market Estimates & Forecasts, 2018 – 2030 (USD Billion)
8.5.4.3 Target Disease Prevalence
8.5.4.4 Competitive Scenario
8.5.4.5 Regulatory Framework
8.5.4.6 Reimbursement Scenario
8.6 Middle East and Africa
8.6.1 Middle East and Africa Biologics Market Estimates & Forecasts, 2018 – 2030 (USD Billion)
8.6.1.1 Target Disease Prevalence
8.6.1.2 Competitive Scenario
8.6.1.3 Regulatory Framework
8.6.1.4 Reimbursement Scenario
8.6.2 South Africa
8.6.2.1 Key Country Dynamics
8.6.2.2 South Africa Biologics Market Estimates & Forecasts, 2018 – 2030 (USD Billion)
8.6.2.3 Target Disease Prevalence
8.6.2.4 Competitive Scenario
8.6.2.5 Regulatory Framework
8.6.2.6 Reimbursement Scenario
8.6.3 Saudi Arabia
8.6.3.1 Key Country Dynamics
8.6.3.2 Saudi Arabia Biologics Market Estimates & Forecasts, 2018 – 2030 (USD Billion)
8.6.3.3 Target Disease Prevalence
8.6.3.4 Competitive Scenario
8.6.3.5 Regulatory Framework
8.6.3.6 Reimbursement Scenario
8.6.4 UAE
8.6.4.1 Key Country Dynamics
8.6.4.2 UAE Biologics Market Estimates & Forecasts, 2018 – 2030 (USD Billion)
8.6.4.3 Target Disease Prevalence
8.6.4.4 Competitive Scenario
8.6.4.5 Regulatory Framework
8.6.4.6 Reimbursement Scenario
8.6.5 KUWAIT
8.6.5.1 Key Country Dynamics
8.6.5.2 Kuwait Biologics Market Estimates & Forecasts, 2018 – 2030 (USD Billion)
8.6.5.3 Target Disease Prevalence
8.6.5.4 Competitive Scenario
8.6.5.5 Regulatory Framework
8.6.5.6 Reimbursement Scenario
Chapter 9. Competitive Landscape
9.1. Company Categorization
9.2. Strategy Mapping
9.2.1. New Product Launch
9.2.2. Partnerships
9.2.3. Acquisition
9.2.4. Collaboration
9.2.5. Funding
9.3. Company Market Share Analysis, 2022
9.4. Company Profiles
9.4.1. Samsung BioLogics
9.4.1.1. Company Overview
9.4.1.2. Financial Performance
9.4.1.3. Product Benchmarking
9.4.1.4. Strategic Initiatives
9.4.2. Amgen
9.4.2.1. Company Overview
9.4.2.2. Financial Performance
9.4.2.3. Product Benchmarking
9.4.2.4. Strategic Initiatives
9.4.3. Novo Nordisk A/S
9.4.3.1. Company Overview
9.4.3.2. Financial Performance
9.4.3.3. Product Benchmarking
9.4.3.4. Strategic Initiatives
9.4.4. AbbVie Inc.
9.4.4.1. Company Overview
9.4.4.2. Financial Performance
9.4.4.3. Product Benchmarking
9.4.4.4. Strategic Initiatives
9.4.5. Sanofi
9.4.5.1. Company Overview
9.4.5.2. Financial Performance
9.4.5.3. Product Benchmarking
9.4.5.4. Strategic Initiatives
9.4.6. Johnson & Johnson Services, Inc
9.4.6.1. Company Overview
9.4.6.2. Financial Performance
9.4.6.3. Product Benchmarking
9.4.6.4. Strategic Initiatives
9.4.7. Celltrion
9.4.7.1. Company Overview
9.4.7.2. Financial Performance
9.4.7.3. Product Benchmarking
9.4.7.4. Strategic Initiatives
9.4.8. Bristol-Myers Squibb Company
9.4.8.1. Company Overview
9.4.8.2. Financial Performance
9.4.8.3. Product Benchmarking
9.4.8.4. Strategic Initiatives
9.4.9. Eli Lilly and Company
9.4.9.1. Company Overview
9.4.9.2. Financial Performance
9.4.9.3. Product Benchmarking
9.4.9.4. Strategic Initiatives

List of Tables

TABLE 1 List of secondary sources
TABLE 2 List of Abbreviations
TABLE 3 Global biologics market estimates& forecasts, by source, 2018 - 2030 (USD Billion)
TABLE 4 Global biologics market estimates& forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 5 Global monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 6 Global diagnostic monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 7 Global therapeutic monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 8 Global monoclonal antibodies market estimates & forecasts, by type, 2018 - 2030 (USD Billion)
TABLE 9 Global biologics market estimates & forecasts, by manufacturing, 2018 - 2030 (USD Billion)
TABLE 10 Global biologics market estimates & forecasts, by therapeutic area, 2018 - 2030 (USD Billion)
TABLE 11 Global oncology biologics market estimates & forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 12 Global infectious diseases biologics market estimates & forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 13 North America biologics market estimates& forecasts, by source, 2018 - 2030 (USD Billion)
TABLE 14 North America biologics market estimates& forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 15 North America monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 16 North America diagnostic monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 17 North America therapeutic monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 18 North America monoclonal antibodies market estimates & forecasts, by type, 2018 - 2030 (USD Billion)
TABLE 19 North America biologics market estimates & forecasts, by manufacturing, 2018 - 2030 (USD Billion)
TABLE 20 North America biologics market estimates & forecasts, by therapeutic area, 2018 - 2030 (USD Billion)
TABLE 21 North America oncology biologics market estimates & forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 22 North America infectious diseases biologics market estimates & forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 23 U.S. biologics market estimates& forecasts, by source, 2018 - 2030 (USD Billion)
TABLE 24 U.S. biologics market estimates& forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 25 U.S. monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 26 U.S. diagnostic monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 27 U.S. therapeutic monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 28 U.S. monoclonal antibodies market estimates & forecasts, by type, 2018 - 2030 (USD Billion)
TABLE 29 U.S. biologics market estimates & forecasts, by manufacturing, 2018 - 2030 (USD Billion)
TABLE 30 U.S. biologics market estimates & forecasts, by therapeutic area, 2018 - 2030 (USD Billion)
TABLE 31 U.S. oncology biologics market estimates & forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 32 U.S. infectious diseases biologics market estimates & forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 33 Canada biologics market estimates& forecasts, by source, 2018 - 2030 (USD Billion)
TABLE 34 Canada biologics market estimates& forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 35 Canada monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 36 Canada diagnostic monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 37 Canada therapeutic monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 38 Canada monoclonal antibodies market estimates & forecasts, by type, 2018 - 2030 (USD Billion)
TABLE 39 Canada biologics market estimates & forecasts, by manufacturing, 2018 - 2030 (USD Billion)
TABLE 40 Canada biologics market estimates & forecasts, by therapeutic area, 2018 - 2030 (USD Billion)
TABLE 41 Canada oncology biologics market estimates & forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 42 Canada infectious diseases biologics market estimates & forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 43 Europe biologics market estimates& forecasts, by source, 2018 - 2030 (USD Billion)
TABLE 44 Europe biologics market estimates& forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 45 Europe monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 46 Europe diagnostic monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 47 Europe therapeutic monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 48 Europe monoclonal antibodies market estimates & forecasts, by type, 2018 - 2030 (USD Billion)
TABLE 49 Europe biologics market estimates & forecasts, by manufacturing, 2018 - 2030 (USD Billion)
TABLE 50 Europe biologics market estimates & forecasts, by therapeutic area, 2018 - 2030 (USD Billion)
TABLE 51 Europe oncology biologics market estimates & forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 52 Europe infectious diseases biologics market estimates & forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 53 Germany biologics market estimates& forecasts, by source, 2018 - 2030 (USD Billion)
TABLE 54 Germany biologics market estimates& forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 55 Germany monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 56 Germany diagnostic monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 57 Germany therapeutic monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 58 Germany monoclonal antibodies market estimates & forecasts, by type, 2018 - 2030 (USD Billion)
TABLE 59 Germany biologics market estimates & forecasts, by manufacturing, 2018 - 2030 (USD Billion)
TABLE 60 Germany biologics market estimates & forecasts, by therapeutic area, 2018 - 2030 (USD Billion)
TABLE 61 Germany oncology biologics market estimates & forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 62 Germany infectious diseases biologics market estimates & forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 63 UK biologics market estimates& forecasts, by source, 2018 - 2030 (USD Billion)
TABLE 64 UK biologics market estimates& forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 65 UK monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 66 UK diagnostic monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 67 UK therapeutic monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 68 UK monoclonal antibodies market estimates & forecasts, by type, 2018 - 2030 (USD Billion)
TABLE 69 UK biologics market estimates & forecasts, by manufacturing, 2018 - 2030 (USD Billion)
TABLE 70 UK biologics market estimates & forecasts, by therapeutic area, 2018 - 2030 (USD Billion)
TABLE 71 UK oncology biologics market estimates & forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 72 UK infectious diseases biologics market estimates & forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 73 France biologics market estimates& forecasts, by source, 2018 - 2030 (USD Billion)
TABLE 74 France biologics market estimates& forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 75 France monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 76 France diagnostic monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 77 France therapeutic monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 78 France monoclonal antibodies market estimates & forecasts, by type, 2018 - 2030 (USD Billion)
TABLE 79 France biologics market estimates & forecasts, by manufacturing, 2018 - 2030 (USD Billion)
TABLE 80 France biologics market estimates & forecasts, by therapeutic area, 2018 - 2030 (USD Billion)
TABLE 81 France oncology biologics market estimates & forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 82 France infectious diseases biologics market estimates & forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 83 Italy biologics market estimates& forecasts, by source, 2018 - 2030 (USD Billion)
TABLE 84 Italy biologics market estimates& forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 85 Italy monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 86 Italy diagnostic monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 87 Italy therapeutic monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 88 Italy monoclonal antibodies market estimates & forecasts, by type, 2018 - 2030 (USD Billion)
TABLE 89 Italy biologics market estimates & forecasts, by manufacturing, 2018 - 2030 (USD Billion)
TABLE 90 Italy biologics market estimates & forecasts, by therapeutic area, 2018 - 2030 (USD Billion)
TABLE 91 Italy oncology biologics market estimates & forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 92 Italy infectious diseases biologics market estimates & forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 93 Spain biologics market estimates& forecasts, by source, 2018 - 2030 (USD Billion)
TABLE 94 Spain biologics market estimates& forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 95 Spain monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 96 Spain diagnostic monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 97 Spain therapeutic monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 98 Spain monoclonal antibodies market estimates & forecasts, by type, 2018 - 2030 (USD Billion)
TABLE 99 Spain biologics market estimates & forecasts, by manufacturing, 2018 - 2030 (USD Billion)
TABLE 100 Spain biologics market estimates & forecasts, by therapeutic area, 2018 - 2030 (USD Billion)
TABLE 101 Spain oncology biologics market estimates & forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 102 Spain infectious diseases biologics market estimates & forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 103 Denmark biologics market estimates& forecasts, by source, 2018 - 2030 (USD Billion)
TABLE 104 Denmark biologics market estimates& forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 105 Denmark monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 106 Denmark diagnostic monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 107 Denmark therapeutic monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 108 Denmark monoclonal antibodies market estimates & forecasts, by type, 2018 - 2030 (USD Billion)
TABLE 109 Denmark biologics market estimates & forecasts, by manufacturing, 2018 - 2030 (USD Billion)
TABLE 110 Denmark biologics market estimates & forecasts, by therapeutic area, 2018 - 2030 (USD Billion)
TABLE 111 Denmark oncology biologics market estimates & forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 112 Denmark infectious diseases biologics market estimates & forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 113 Sweden biologics market estimates& forecasts, by source, 2018 - 2030 (USD Billion)
TABLE 114 Sweden biologics market estimates& forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 115 Sweden monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 116 Sweden diagnostic monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 117 Sweden therapeutic monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 118 Sweden monoclonal antibodies market estimates & forecasts, by type, 2018 - 2030 (USD Billion)
TABLE 119 Sweden biologics market estimates & forecasts, by manufacturing, 2018 - 2030 (USD Billion)
TABLE 120 Sweden biologics market estimates & forecasts, by therapeutic area, 2018 - 2030 (USD Billion)
TABLE 121 Sweden oncology biologics market estimates & forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 122 Sweden infectious diseases biologics market estimates & forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 123 Norway biologics market estimates& forecasts, by source, 2018 - 2030 (USD Billion)
TABLE 124 Norway biologics market estimates& forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 125 Norway monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 126 Norway diagnostic monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 127 Norway therapeutic monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 128 Norway monoclonal antibodies market estimates & forecasts, by type, 2018 - 2030 (USD Billion)
TABLE 129 Norway biologics market estimates & forecasts, by manufacturing, 2018 - 2030 (USD Billion)
TABLE 130 Norway biologics market estimates & forecasts, by therapeutic area, 2018 - 2030 (USD Billion)
TABLE 131 Norway oncology biologics market estimates & forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 132 Norway infectious diseases biologics market estimates & forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 133 Asia Pacific biologics market estimates& forecasts, by source, 2018 - 2030 (USD Billion)
TABLE 134 Asia Pacific biologics market estimates& forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 135 Asia Pacific monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 136 Asia Pacific diagnostic monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 137 Asia Pacific therapeutic monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 138 Asia Pacific monoclonal antibodies market estimates & forecasts, by type, 2018 - 2030 (USD Billion)
TABLE 139 Asia Pacific biologics market estimates & forecasts, by manufacturing, 2018 - 2030 (USD Billion)
TABLE 140 Asia Pacific biologics market estimates & forecasts, by therapeutic area, 2018 - 2030 (USD Billion)
TABLE 141 Asia Pacific oncology biologics market estimates & forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 142 Asia Pacific infectious diseases biologics market estimates & forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 143 Japan biologics market estimates& forecasts, by source, 2018 - 2030 (USD Billion)
TABLE 144 Japan biologics market estimates& forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 145 Japan monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 146 Japan diagnostic monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 147 Japan therapeutic monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 148 Japan monoclonal antibodies market estimates & forecasts, by type, 2018 - 2030 (USD Billion)
TABLE 149 Japan biologics market estimates & forecasts, by manufacturing, 2018 - 2030 (USD Billion)
TABLE 150 Japan biologics market estimates & forecasts, by therapeutic area, 2018 - 2030 (USD Billion)
TABLE 151 Japan oncology biologics market estimates & forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 152 Japan infectious diseases biologics market estimates & forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 153 China biologics market estimates& forecasts, by source, 2018 - 2030 (USD Billion)
TABLE 154 China biologics market estimates& forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 155 China monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 156 China diagnostic monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 157 China therapeutic monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 158 China monoclonal antibodies market estimates & forecasts, by type, 2018 - 2030 (USD Billion)
TABLE 159 China biologics market estimates & forecasts, by manufacturing, 2018 - 2030 (USD Billion)
TABLE 160 China biologics market estimates & forecasts, by therapeutic area, 2018 - 2030 (USD Billion)
TABLE 161 China oncology biologics market estimates & forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 162 China infectious diseases biologics market estimates & forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 163 India biologics market estimates& forecasts, by source, 2018 - 2030 (USD Billion)
TABLE 164 India biologics market estimates& forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 165 India monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 166 India diagnostic monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 167 India therapeutic monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 168 India monoclonal antibodies market estimates & forecasts, by type, 2018 - 2030 (USD Billion)
TABLE 169 India biologics market estimates & forecasts, by manufacturing, 2018 - 2030 (USD Billion)
TABLE 170 India biologics market estimates & forecasts, by therapeutic area, 2018 - 2030 (USD Billion)
TABLE 171 India oncology biologics market estimates & forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 172 India infectious diseases biologics market estimates & forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 173 Australia biologics market estimates& forecasts, by source, 2018 - 2030 (USD Billion)
TABLE 174 Australia biologics market estimates& forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 175 Australia monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 176 Australia diagnostic monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 177 Australia therapeutic monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 178 Australia monoclonal antibodies market estimates & forecasts, by type, 2018 - 2030 (USD Billion)
TABLE 179 Australia biologics market estimates & forecasts, by manufacturing, 2018 - 2030 (USD Billion)
TABLE 180 Australia biologics market estimates & forecasts, by therapeutic area, 2018 - 2030 (USD Billion)
TABLE 181 Australia oncology biologics market estimates & forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 182 Australia infectious diseases biologics market estimates & forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 183 South Korea biologics market estimates& forecasts, by source, 2018 - 2030 (USD Billion)
TABLE 184 South Korea biologics market estimates& forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 185 South Korea monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 186 South Korea diagnostic monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 187 South Korea therapeutic monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 188 South Korea monoclonal antibodies market estimates & forecasts, by type, 2018 - 2030 (USD Billion)
TABLE 189 South Korea biologics market estimates & forecasts, by manufacturing, 2018 - 2030 (USD Billion)
TABLE 190 South Korea biologics market estimates & forecasts, by therapeutic area, 2018 - 2030 (USD Billion)
TABLE 191 South Korea oncology biologics market estimates & forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 192 South Korea infectious diseases biologics market estimates & forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 193 Thailand biologics market estimates& forecasts, by source, 2018 - 2030 (USD Billion)
TABLE 194 Thailand biologics market estimates& forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 195 Thailand monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 196 Thailand diagnostic monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 197 Thailand therapeutic monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 198 Thailand monoclonal antibodies market estimates & forecasts, by type, 2018 - 2030 (USD Billion)
TABLE 199 Thailand biologics market estimates & forecasts, by manufacturing, 2018 - 2030 (USD Billion)
TABLE 200 Thailand biologics market estimates & forecasts, by therapeutic area, 2018 - 2030 (USD Billion)
TABLE 201 Thailand oncology biologics market estimates & forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 202 Thailand infectious diseases biologics market estimates & forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 203 Latin America biologics market estimates & forecasts, by source, 2018 - 2030 (USD Billion)
TABLE 204 Latin America biologics market estimates & forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 205 Latin America monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 206 Latin America diagnostic monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 207 Latin America therapeutic monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 208 Latin America monoclonal antibodies market estimates & forecasts, by type, 2018 - 2030 (USD Billion)
TABLE 209 Latin America biologics market estimates & forecasts, by manufacturing, 2018 - 2030 (USD Billion)
TABLE 210 Latin America biologics market estimates & forecasts, by therapeutic area, 2018 - 2030 (USD Billion)
TABLE 211 Latin America oncology biologics market estimates & forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 212 Latin America infectious diseases biologics market estimates & forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 213 Brazil biologics market estimates& forecasts, by source, 2018 - 2030 (USD Billion)
TABLE 214 Brazil biologics market estimates& forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 215 Brazil monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 216 Brazil diagnostic monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 217 Brazil therapeutic monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 218 Brazil monoclonal antibodies market estimates & forecasts, by type, 2018 - 2030 (USD Billion)
TABLE 219 Brazil biologics market estimates & forecasts, by manufacturing, 2018 - 2030 (USD Billion)
TABLE 220 Brazil biologics market estimates & forecasts, by therapeutic area, 2018 - 2030 (USD Billion)
TABLE 221 Brazil oncology biologics market estimates & forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 222 Brazil infectious diseases biologics market estimates & forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 223 Mexico biologics market estimates& forecasts, by source, 2018 - 2030 (USD Billion)
TABLE 224 Mexico biologics market estimates& forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 225 Mexico monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 226 Mexico diagnostic monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 227 Mexico therapeutic monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 228 Mexico monoclonal antibodies market estimates & forecasts, by type, 2018 - 2030 (USD Billion)
TABLE 229 Mexico biologics market estimates & forecasts, by manufacturing, 2018 - 2030 (USD Billion)
TABLE 230 Mexico biologics market estimates & forecasts, by therapeutic area, 2018 - 2030 (USD Billion)
TABLE 231 Mexico oncology biologics market estimates & forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 232 Mexico infectious diseases biologics market estimates & forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 233 Argentina biologics market estimates& forecasts, by source, 2018 - 2030 (USD Billion)
TABLE 234 Argentina biologics market estimates& forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 235 Argentina monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 236 Argentina diagnostic monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 237 Argentina therapeutic monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 238 Argentina monoclonal antibodies market estimates & forecasts, by type, 2018 - 2030 (USD Billion)
TABLE 239 Argentina biologics market estimates & forecasts, by manufacturing, 2018 - 2030 (USD Billion)
TABLE 240 Argentina biologics market estimates & forecasts, by therapeutic area, 2018 - 2030 (USD Billion)
TABLE 241 Argentina oncology biologics market estimates & forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 242 Argentina infectious diseases biologics market estimates & forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 243 MEA biologics market estimates& forecasts, by source, 2018 - 2030 (USD Billion)
TABLE 244 MEA biologics market estimates& forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 245 MEA monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 246 MEA diagnostic monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 247 MEA therapeutic monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 248 MEA monoclonal antibodies market estimates & forecasts, by type, 2018 - 2030 (USD Billion)
TABLE 249 MEA biologics market estimates & forecasts, by manufacturing, 2018 - 2030 (USD Billion)
TABLE 250 MEA biologics market estimates & forecasts, by therapeutic area, 2018 - 2030 (USD Billion)
TABLE 251 MEA oncology biologics market estimates & forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 252 MEA infectious diseases biologics market estimates & forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 253 South Africa biologics market estimates& forecasts, by source, 2018 - 2030 (USD Billion)
TABLE 254 South Africa biologics market estimates& forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 255 South Africa monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 256 South Africa diagnostic monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 257 South Africa therapeutic monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 258 South Africa monoclonal antibodies market estimates & forecasts, by type, 2018 - 2030 (USD Billion)
TABLE 259 South Africa biologics market estimates & forecasts, by manufacturing, 2018 - 2030 (USD Billion)
TABLE 260 South Africa biologics market estimates & forecasts, by therapeutic area, 2018 - 2030 (USD Billion)
TABLE 261 South Africa oncology biologics market estimates & forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 262 South Africa infectious diseases biologics market estimates & forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 263 Saudi Arabia biologics market estimates& forecasts, by source, 2018 - 2030 (USD Billion)
TABLE 264 Saudi Arabia biologics market estimates& forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 265 Saudi Arabia monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 266 Saudi Arabia diagnostic monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 267 Saudi Arabia therapeutic monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 268 Saudi Arabia monoclonal antibodies market estimates & forecasts, by type, 2018 - 2030 (USD Billion)
TABLE 269 Saudi Arabia biologics market estimates & forecasts, by manufacturing, 2018 - 2030 (USD Billion)
TABLE 270 Saudi Arabia biologics market estimates & forecasts, by therapeutic area, 2018 - 2030 (USD Billion)
TABLE 271 Saudi Arabia oncology biologics market estimates & forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 272 Saudi Arabia infectious diseases biologics market estimates & forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 273 UAE biologics market estimates& forecasts, by source, 2018 - 2030 (USD Billion)
TABLE 274 UAE biologics market estimates& forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 275 UAE monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 276 UAE diagnostic monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 277 UAE therapeutic monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 278 UAE monoclonal antibodies market estimates & forecasts, by type, 2018 - 2030 (USD Billion)
TABLE 279 UAE biologics market estimates & forecasts, by manufacturing, 2018 - 2030 (USD Billion)
TABLE 280 UAE biologics market estimates & forecasts, by therapeutic area, 2018 - 2030 (USD Billion)
TABLE 281 UAE oncology biologics market estimates & forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 282 UAE infectious diseases biologics market estimates & forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 283 Kuwait biologics market estimates& forecasts, by source, 2018 - 2030 (USD Billion)
TABLE 284 Kuwait biologics market estimates& forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 285 Kuwait monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 286 Kuwait diagnostic monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 287 Kuwait therapeutic monoclonal antibodies market estimates & forecasts, by application, 2018 - 2030 (USD Billion)
TABLE 288 Kuwait monoclonal antibodies market estimates & forecasts, by type, 2018 - 2030 (USD Billion)
TABLE 289 Kuwait biologics market estimates & forecasts, by manufacturing, 2018 - 2030 (USD Billion)
TABLE 290 Kuwait biologics market estimates & forecasts, by therapeutic area, 2018 - 2030 (USD Billion)
TABLE 291 Kuwait oncology biologics market estimates & forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 292 Kuwait infectious diseases biologics market estimates & forecasts, by product, 2018 - 2030 (USD Billion)
TABLE 293 Company Overview
TABLE 294 Financial Performance
TABLE 295 Product Benchmarking
TABLE 296 Strategic Initiatives

★調査レポート[世界の生物製剤市場2023-2030：由来別（微生物、哺乳類）、製品別（MAB、組換えタンパク質、アンチセンス・RNAi）、疾患カテゴリー別、製造別、地域別] (コード：GRV23JUN020)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の生物製剤市場2023-2030：由来別（微生物、哺乳類）、製品別（MAB、組換えタンパク質、アンチセンス・RNAi）、疾患カテゴリー別、製造別、地域別]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 生物製剤の世界市場2023-2029：モノクローナル抗体、ワクチン、組換えタンパク質、アンチセンス、RNAi
  • 世界の哺乳類細胞発酵技術市場2023-2030：種類別、用途別（モノクローナル抗体、組換えタンパク質）、エンドユーザー別、地域別
  • 世界の先進治療薬CDMO市場2023-2030：製品別（遺伝子治療、細胞治療、組織工学）、フェーズ別、疾患別、地域別
  • 世界の静脈注射用鉄剤市場2023-2030：製品別（鉄デキストラン、鉄スクロース鉄、カルボキシマルトース第2鉄）、用途別（慢性腎臓病、炎症性腸疾患、がん）、地域別
  • 世界のペプチド薬物複合体（PDC）市場（2023-2030）：製品別（ルテチウム、メルフルフェン、ANG1005、BT1718、CBX-12、その他）、種類別（診断薬、治療薬）、地域別
  • 世界の血友病市場2023-2030：種類別（血友病A）、治療種類別（オンデマンド）、治療法別（遺伝子治療、モノクローナル抗体）、流通チャネル別、地域別
  • 世界のブランドジェネリック市場2023-2030：薬物クラス別（アルキル化剤、代謝拮抗剤、抗高血圧剤）、用途別、投与経路別、流通チャネル別、地域別
  • 世界のペプチド治療薬市場2023-2030：用途別、種類別（ジェネリック、革新的）、メーカー種類別、投与経路別、合成技術別、地域別
  • 世界のエリスロポエチン薬市場2023-2030：種類別（生物製剤、バイオシミラー）、製品別（エリスロポエチン、ダルベポエチン-アルファ）、用途別（がん、腎臓病、神経）、地域別

    • ◆H&Iグローバルリサーチのお客様（例）◆